• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

News &
Media

  • Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism

    22 July 2022
    Stockhead

    Neurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.

    View More
  • Neurotech Releases ASD Medical Cannabis Study Results

    12 July 2022
    The Hemp Gazette

    Australia’s Neurotech International Limited (ASX: NTI) has announced what it says are successful outcomes of its medical cannabis formulation on key behavioural issues impacting kids with autism.

    View More
  • Neurotech International (ASX:NTI) Webinar – Breakthrough results with NTI164 in paediatric ASD

    8 July 2022
    Webinar
    View More
  • Neurotech study says cannabis could be key to helping kids on the spectrum reach potential

    8 July 2022
    Stockhead

    Neurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).

    View More
  • Neurotech study says cannabis could be key to helping kids on the spectrum reach potential

    8 July 2022
    The Australian

    Neurotech has released promising results from a world-first study of a medicinal cannabis product which could be a game changer in treating children with autism.

    View More
  • Neurotech study finds children with autism benefit from cannabis product

    8 July 2022
    Maket Index

    Neurotech International (ASX:NTI) has today announced its patent NTI164 product has been proven to reduce ASD symptoms in children and teenagers.

    View More
  • Neurotech International announces breakthrough results from autism study

    8 July 2022
    Cannabiz

    Neurotech International has announced breakthrough results from a clinical trial of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).

    View More
  • Neurotech International (ASX:NTI) announces “breakthrough” results for medicinal cannabis study

    8 July 2022
    The Market Herald

    Neurotech International (NTI) has reported that 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with autism spectrum disorder (ASD).

    View More
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug

    8 July 2022
    The Sentiment

    The cannabinoid based drug, licensed from Dolve Cann Global is the world’s first full-spectrum medicinal cannabis product (with less than 0.3% THC).

    View More
Previous
1 2 3 4 5
Next

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1679490947anoit1679490947anret1679490947nihce1679490947torue1679490947n@ofn1679490947i1679490947

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus